Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: The role of baseline serum epoetin level

Clinical and Translational Oncology

Volumn 10, Issue 8, 2008, Pages 486-492

  Sanz Ortiz, Jaime ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Anemia; Drug resistance; Erythropoiesis stimulating agents; Erythropoietin; Neoplasms; Risk factors

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD; DRUG EFFECT; ERYTHROPOIESIS; HUMAN; NEOPLASM; PREDICTION AND FORECASTING; REVIEW;

ANEMIA; ANTINEOPLASTIC AGENTS; EPOETIN ALFA; ERYTHROPOIESIS; HEMATINICS; HUMANS; NEOPLASMS; PREDICTIVE VALUE OF TESTS;

EID: 54549084416     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-008-0237-2     Document Type: Review

References (79)

1. Groopman JE, Itri LM (1999) Chemotherapy-induced anaemia in adults: incident and treatment. J Natl Cancer Inst 91:1616-1634 (Pubitemid 29479929)
2. Charuruks N, Voravud N, Limpanasithikul W (2001) Ratio of baseline erythropoietin (EPO) level and corrected reticulocyte count as an indicator for a favorable response to recombinant human erythropoietin (rhEPO) therapy in anaemic cancer patients. J Clin Lab Anal 15:260-266 (Pubitemid 32896023)
3. Benson EW, Hardy R, Chaffin H et al (2000) New automated chemiluminescent assay for erythropoietin. J Clin Lab Anal 14:271-273
4. Canaparo R, Casale F, Muntoni E et al (2000) Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Brit J Pharmacol 50:146-153 (Pubitemid 30612032)
5. Tas F, Eralp Y, Basaran M et al (2002) Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol 25:371-379 (Pubitemid 34864032)
6. Del Mastro L, Gennari A, Donati S (1999) Chemotherapy of non-small-cell lung cancer: role of erythropoietin in the management of anemia. Ann Oncol 10:S91-S94 (Pubitemid 29522791)
7. Demetri GD (2001) Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 84:31-37 (Pubitemid 32453433)
8. Rajeswaran A, Trojan A, Burnand B, Giannelli M (2008) Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 59:1-11.
9. Ludwig H, Van Belle S. Barret-Lee P et al (2004) The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J of Cancer 40:2293-2306 (Pubitemid 39348881)
10. Fisher JW (2003) Erythropoietin: physiology and pharmacology update. EBM 228:1-14 (Pubitemid 36077622)
11. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG (2007) Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin. Biochim Biophys Acta 1776:1-9 (Pubitemid 47332076)
12. P. Ghezzi and M. Brines (2004) Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 11:S37-S44 (Pubitemid 39136797)
13. Koury MJ, Sawyer ST, Brant SJ (2002) New insights into erythropoiesis Curr Opin Hematol 9:93-100 (Pubitemid 34171483)
14. Langer CJ, Hirsch FR, Cortés-Funes H et al (2003) Targeted molecular mechanisms of epoetin alpha. Lung Cancer 41:S133-S145 (Pubitemid 36819005)
15. Boogaerts M (2006) Pleiotropic effects of erythropoietin in neuronal and vascular systems. Curr Med Res Opin 22(Suppl. 4):15-22
16. Brines M, Cerami A (2005) Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6:484-494 (Pubitemid 40769173)
17. Maraveyas A, Pettengell R (1998) What is the role of erythropoietin in patients with solid tumors? Ann Oncol 9:255-260
18. Seidenfeld J, Piper M, Bohlius J et al (2006) Comparative effectiveness of epoetin and darbepoetin for managing anaemia in patients undergoing cancer treatment. Comparative Effectiveness Review No. 3 (Prepared by the BlueCross and BlueShield Association Technology Evaluation Center Evidence-Based Practice Center under Contract No. 290-02-0026). Agency for Healthcare Research and Quality. http://www.effectivehealthcare.ahrq.gov. (Cited 23 May 2006)
19. Jones M, Schenkel B, Just J et al (2004) Epoetin alpha improves quality of life in patients with cancer: results of metaanalysis. Cancer 101: 1720-1732. (Pubitemid 39314735)
20. Erratum in: (2005) Cancer 103:1984
21. Hedenus M, Vansteenkiste J, Kotasek D et al (2005) Darbepoetin alpha for the treatment of chemotherapy-induced anaemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 23:6941-6948
22. Bohlius J, Wilson J, Seidenfeld J et al (2006) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 3:CD003407
23. Rizzo JD, Somerfield MR, Hagerty KL et al (2008) Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. J Clin Oncol 26:132-149
24. Bokemeyer C, Aapro MS, Courdi A et al (2007) Erythropoiesis-stimulating agents-ESAs: The 2007 position of the EORTC working party. Presented at Live Expert, e-European School of Oncology, 21 September 2007. http://services. choruscall.eu/links/eso070921.html. Cited 24 December 2007
25. National Comprehensive Cancer Network (NCCN) (2007) Practice guidelines in oncology: cancer- and treatment-related anaemia. Ver. 3. Jenkintown, PA: NCCN. www.nccn.org/professionals/physician-gls/PDF/anaemia.pdf. Cited 24 December 2007
26. (2004) Epoetin: for better or for worse?[editorial]. Lancet Oncol 5:1
27. Bohlius J, Langensiepen S, Schwarzer G et al (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97:489-498 (Pubitemid 40590430)
28. Lipsic E, van der Meer P, Voors AA et al (2006) A single bolus of a long-acting erythropoietin analogue darbepoetin alpha in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 20: 135-141 (Pubitemid 43876097)
29. Yasuda Y, Fujita Y, Matsuo T et al (2003) Erythropoietin regulates tumor growth on the human malignancies. Carcinogenesis 24:1021-1029 (Pubitemid 36833185)
30. Leyland-Jones B, Semiglazov V, Pawlicki M et al (2005) Maintaining normal haemoglobin levels with epoetin alpha in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23: 5960-5972
31. Silva M, Benito A, Sanz C (1999) Erythropoietin can induce the expression of bcl-x through Stat5 in erythropoietin dependent progenitor cell lines. J Biol Chem 274:22165-22169
32. Henke M, Laszig R, Rübe C et al (2003) Erythropoietin to treat head an neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 362:1255-1260 (Pubitemid 37324251)
33. LaMontagne KR, Butler J, Marshall DJ et al (2006) Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 5: 347-355
34. Hardee ME, Rabbani ZN, Arcasoy MO et al (2006) Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther 5:356-361
35. Kirkpatrick JP, Hardee ME, Snyder SA et al (2006) The effect of darbepoetin alpha on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma. Radiat Res 165:192-201 (Pubitemid 43153132)
36. Kjellen E, Sasaki Y, Kjellstrom J et al (2006) Recombinant erythropoietin beta enhances growth of xenografted human squamous cell carcinoma of the head and neck after surgical trauma. Acta Otolaryngol 126:545-547
37. Pinel S, Barberi-Heyob M, Cohen-Jonathan E et al (2004) Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts. Int J Radiat Oncol Biol Phys 59:250-259 (Pubitemid 38501530)
38. Drüeke T (2001) Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 16(Suppl 7):25-28 (Pubitemid 33062119)
39. Beguin Y (1998) Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer. Med Oncol 15:S38-S46 (Pubitemid 28429602)
40. Thomas C, Thomas L (2002) Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 48:1066-1076 (Pubitemid 34680903)
41. Katodritou E, Terpos E, Zervas K et al (2007) Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. Ann Hematol 86:369-376 (Pubitemid 46477302)
42. Rizzo JD, Seidenfeld J, Piper M et al (2001) Erythropoietin: a paradigm for the development of practice guidelines. Hematology (Am Soc Hematol Educ Program) 1:10-30
43. Braun J, Lindner K, Schreiber M et al (1997) Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 12:1173-1181 (Pubitemid 27230553)
44. Goram AL (2000) Factors and predictors of response with epoetin alpha for chemotherapy-related anemia. J Pharm Technol 16:227-235
45. Cazzola M, Ponchio L, Pedrotti C et al (1996) Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 81:434-441
46. Littlewood TJ, Zagari M, Pallister P (2005) Pretreatment erythropoietin levels cannot be used to predict individual response to epoetin alpha in anaemic cancer patients. Curr Med Res Opin 21(Suppl 2):S19-S21
47. Kolesar JM, Duren BA, Baranski BG (2004) Retrospective evaluation of response to epoetin alpha in patients with hematologic disorders. J Oncol Pharm Pract 10:1-6 (Pubitemid 38344491)
48. Littlewood TJ, Zagari M, Pallister C et al (2003) Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist 8:99-107 (Pubitemid 36232360)
49. Glaspy J, Cavill I (1999) Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology 13:461-473
50. Henry D, Abels R, Larholt K (1995) Prediction of response to recombinant human erythropoietin (r-HuEPO/Epoetin-alpha) therapy in cancer patients. Blood 85:1676-1678
51. Ludwig H, Fritz E, Leitgeb C et al (1994) Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84:1056-1063 (Pubitemid 24245869)
52. Demetri G, Kris M, Wade J et al (1998) Qualityof-life benefit in chemotherapy patients treated with epoetin alpha is independent of disease response or tumor type: results from a Prospective Community Oncology Study. J Clin Oncol. 16: 3412-3425 (Pubitemid 28481641)
53. Boccia R, Malik IA, Raja V et al (2006) Darbepoetin alpha administered every three weeks is effective for the treatment of chemotherapy-induced anaemia. Oncologist 11: 409-417
54. Trelle S, Piper M, Bohlius J et al (2006) Predictive factors of response to recombinant human erythropoietin: quality and results of studies identified by a systematic review. Onkologie 29(Suppl 3):66
55. Österborg, M.A. Boogaerts, R. Cimino et al (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma: a randomized multicenter study. Blood 87:2675-2682 (Pubitemid 26102216)
56. Boogaerts M, Coiffier B, Kainz C (2003) Impact of epoetin β on quality of life in patients with malignant disease. Brit J. Cancer 88:988-995 (Pubitemid 36560764)
57. Hedenus M, Adriansson M, San Miguel J et al (2003) Efficacy and safety of darbepoetin alpha in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebocontrolled study. Brit J Haematol 122:394-403 (Pubitemid 36951623)
58. Steinmetz T, Hellmich M, Neise M et al (2007) Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors. Oncologist 12:748-755 (Pubitemid 47036209)
59. Belon J, Cervera JM, Martinez A et al (2006) Darbepoetin alpha at weekly fixed doses. Clinical experience in Spanish centers. Drugs Today (Barc) 42(Suppl 10):1-12
60. Agoram B, Heatherington AC, Gastonguay MR (2006) Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alpha in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AAPS J 8(3):E552-563
61. Ross SD, Allen IE, Probst CA et al (2007) Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 12:1264-1273 (Pubitemid 350106357)
62. Kato A, Tsuji T, Luo J et al (2008) Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 28:115-121 (Pubitemid 350126501)
63. Hedenus M, Hansen S, Taylor K et al (2002) Randomized, dose-finding study of darbepoetin alpha in anemic patients with lymphoproliferative malignancies. Brit J Cancer 119:79-86 (Pubitemid 35176501)
64. Glimelius B, Linné T, Hoffman et al (1998) Epoetin beta in the treatment of anaemia in patients with advanced gastrointestinal cancer. J Clin Oncol 16:434-440 (Pubitemid 28135584)
65. Cazzola M, Diethelm M, Battistel B et al (1995) Recombinant human erythropoietin in the anaemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 86: 4446-4453
66. Cazzola M, Beguin Y, Kloczko J et al (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Brit J Cancer 122:386-393 (Pubitemid 36951622)
67. Hellstrom-Lindberg E, Negrin R, Stein R et al (1997) Erythroid response to treatment with GCSF plus erythropoietin for the anemia of patients with myelodysplastic syndromes: proposal for a predictive model. Brit J Haematol 99:344-351 (Pubitemid 27497565)
68. Fjornes T, Wiedemann GJ, Sack K et al (1998) Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anemic tumor patients on chemotherapy. Oncol Rep 5:81-86 (Pubitemid 28039824)
69. Canon J, Vansteenkiste J, Bodoky G et al (2006) Randomized double -blind, active-controlled trial of every-3-week Darbepoetin alpha for the treatment of chemotherapy induced anaemia. J Nat Can Inst 98:273-283
70. Glaspy J, Demetri G, Cremieux P (1999) Does baseline endogenous erythropoietin level impact haemoglobin (Hb) response to r-HuEPO. Blood 94(10 Suppl. 1 Part 2):15b
71. Kostova G, Siljanovski N (2005) Erythropoietin production in patients with malignant lymphoma. Prilozi 26:157-168
72. Ozguroglu M, Arun B, Demir G et al (2000) Serum erythropoietin level in anemic cancer patients. Mescal Oncology 17:29-34 (Pubitemid 30159164)
73. Fujisaka Y, Tamura T, Ohe Y et al (2006) Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients. Jpn J Clin Oncol 36:477-482 (Pubitemid 44592674)
74. Charuruks N, Limpanasithikul W, Voravud N et al (2000) Erythropoietin level and haematologic parameters in healthy adults. J Med Assoc Thai 83: 1267-1273 (Pubitemid 33711264)
75. Yamazaki C, Watanabe Y, Sakamoto N (1993) Pharmacokinetic study of recombinant human erythropoietin treatment in pre-dialysis end stage renal disease patients. Japanese J Nephrol 35: 1233-1242 (Pubitemid 24023035)
76. Vansteenkiste J, Pirker R, Massuti B et al (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alpha in lung cancer patients receiving chemotherapy. J Natl Cancer I 94:1211-1220 (Pubitemid 34993871)
77. Heatherington AC, Glaspy J, Kotasek D et al (2001) Changes endogenous erythropoietin and the pharmacokinetics of darbepoetin alpha in patients with non-myeloid malignancies receiving chemotherapy. Blood 98:298a-299a (Pubitemid 33787355)
78. Kaczorowska-Hac B, Balcerska A (2003) Endogenous erythropoietin levels in children with malignancies disorders. Acta Haematol Pol 34:231-237 (Pubitemid 37039441)
79. Aapro M, Abraham I, Bokemeyer C et al (2008) The background and methodology of the Anaemia Cancer Treatment (ACT) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidencebased guidelines. Support Care Cancer 16:193-200